{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:03:26Z","timestamp":1784523806389,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,19]]},"DOI":"10.7759\/cureus.112979","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:50:32Z","timestamp":1784523032000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum Orexin A Levels and Heart Rate Variability Parameters in Newly Diagnosed, Treatment-Na\u00efve Type 2 Diabetes Mellitus: A Case-Control Study"],"prefix":"10.7759","author":[{"given":"Abebe T","family":"Gebrye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Dutt Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Rijhwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md S","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi P","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al.. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019, 157:107843. 10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1627_21","article-title":"Epidemiology of type 2 diabetes in India","volume":"69","author":"Pradeepa R","year":"2021","unstructured":"Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021, 69:2932-8. 10.4103\/ijo.IJO_1627_21","journal-title":"Indian J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00095-7","article-title":"Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications\u2014the French multicenter study","volume":"52","author":"Valensi P","year":"2003","unstructured":"Valensi P, Pari\u00e8s J, Attali JR, et al.. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications\u2014the French multicenter study. Metabolism. 2003, 52:815-20. 10.1016\/S0026-0495(03)00095-7","journal-title":"Metabolism"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.5.1553","article-title":"Diabetic autonomic neuropathy","volume":"26","author":"Vinik AI","year":"2003","unstructured":"Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003, 26:1553-79. 10.2337\/diacare.26.5.1553","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2367","article-title":"Both prediabetes and type 2 diabetes are associated with lower heart rate variability: the Maastricht study","volume":"43","author":"Coopmans C","year":"2020","unstructured":"Coopmans C, Zhou TL, Henry RM, et al.. Both prediabetes and type 2 diabetes are associated with lower heart rate variability: the Maastricht study. Diabetes Care. 2020, 43:1126-33. 10.2337\/dc19-2367","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/147323000603400308","article-title":"Heart rate variability in diabetes patients","volume":"34","author":"Kudat H","year":"2006","unstructured":"Kudat H, Akkaya V, Sozen AB, et al.. Heart rate variability in diabetes patients. J Int Med Res. 2006, 34:291-6. 10.1177\/147323000603400308","journal-title":"J Int Med Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5147468","article-title":"Silymarin in type 2 diabetes mellitus: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"2016","author":"Voroneanu L","year":"2016","unstructured":"Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. Silymarin in type 2 diabetes mellitus: a systematic review and meta\u2010analysis of randomized controlled trials. J Diabetes Res. 2016, 2016:5147468. 10.1155\/2016\/5147468","journal-title":"J Diabetes Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a014868","article-title":"Heart rate variability: standards of measurement, physiological interpretation, and clinical use","volume":"17","author":"Malik M","year":"1996","unstructured":"Malik M, Bigger JT, Camm AJ, et al.. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Eur Heart J. 1996, 17:354-81. 10.1093\/oxfordjournals.eurheartj.a014868","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90795-8","article-title":"Decreased heart rate variability and its association with increased mortality after acute myocardial infarction","volume":"59","author":"Kleiger RE","year":"1987","unstructured":"Kleiger RE, Miller JP, Bigger JT, et al.. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987, 59:256-62. 10.1016\/0002-9149(87)90795-8","journal-title":"Am J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai T","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, et al.. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998, 92:573-85. 10.1016\/S0092-8674(00)80949-6","journal-title":"Cell"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea L","year":"1998","unstructured":"de Lecea L, Kilduff TS, Peyron C, et al.. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998, 95:322-7. 10.1073\/pnas.95.1.322","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell TE","year":"2011","unstructured":"Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011, 51:243-66. 10.1146\/annurev-pharmtox-010510-100528","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref13","article-title":"Association of circulating orexin-A level with metabolic risk factors in North Indian pre-menopausal women","volume":"4","author":"Gupta V","year":"2015","unstructured":"Gupta V, Mishra S, Kumar S, et al.. Association of circulating orexin-A level with metabolic risk factors in North Indian pre-menopausal women. Indian J Physiol Pharmacol. 2015, 4:422-7.","journal-title":"Indian J Physiol Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-019-00728-z","article-title":"Serum level of orexin A and its correlation with metabolic risk factors in type 2 diabetes mellitus patients","volume":"39","author":"Rani M","year":"2019","unstructured":"Rani M, Kumar R, Krishan P, et al.. Serum level of orexin A and its correlation with metabolic risk factors in type 2 diabetes mellitus patients. Int J Diabetes Dev Ctries. 2019, 39:647-53. 10.1007\/s13410-019-00728-z","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref15","article-title":"Chronic orexin-A (hypocretin-1) treatment of type 2 diabetic rats improves glucose control and beta-cell functions","volume":"5","author":"Kaczmarek P","year":"2017","unstructured":"Kaczmarek P, Skrzypski M, Pruszynska-Oszmalek E, et al.. Chronic orexin-A (hypocretin-1) treatment of type 2 diabetic rats improves glucose control and beta-cell functions. J Physiol Pharmacol. 2017, 5:669-81.","journal-title":"J Physiol Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron C","year":"1998","unstructured":"Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998, 18:9996-10015. 10.1523\/JNEUROSCI.18-23-09996.1998","journal-title":"J Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013, 310:2191-4. 10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"ref18","article-title":"VITROS Chemistry Products HbA1c Reagent Kit, VITROS Chemistry Products Calibrator Kit 31, VITROS Chemistry Products %A1c Performance Verifiers I and II","author":"Ortho-Clinical Diagnostics","year":"2015","unstructured":"Ortho-Clinical Diagnostics, Inc.. VITROS Chemistry Products HbA1c Reagent Kit, VITROS Chemistry Products Calibrator Kit 31, VITROS Chemistry Products %A1c Performance Verifiers I and II. U.S. Food and Drug Administration, Silver Spring, MD; 2015."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald WT","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18:499-502. 10.1093\/clinchem\/18.6.499","journal-title":"Clin Chem"},{"key":"ref20","article-title":"Instructions for Use: Human Orexin A (OXA) Competitive ELISA Kit","author":"Fine Biotech Kit","year":"2019","unstructured":"Fine Biotech Kit. Instructions for Use: Human Orexin A (OXA) Competitive ELISA Kit. FineTest, Wuhan, China; 2019."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040223","article-title":"Cardiac autonomic activity and type II diabetes mellitus","volume":"108","author":"Manzella D","year":"2005","unstructured":"Manzella D, Paolisso G. Cardiac autonomic activity and type II diabetes mellitus. Clin Sci (Lond). 2005, 108:93-9. 10.1042\/CS20040223","journal-title":"Clin Sci (Lond)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/apha.12963","article-title":"Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats","volume":"222","author":"Fan Y","year":"2018","unstructured":"Fan Y, Jiang E, Hahka T, Chen QH, Yan J, Shan Z. Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats. Acta Physiol (Oxf). 2018, 222:12963. 10.1111\/apha.12963","journal-title":"Acta Physiol (Oxf)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/509762-serum-orexin-a-levels-and-heart-rate-variability-parameters-in-newly-diagnosed-treatment-nave-type-2-diabetes-mellitus-a-case-control-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:50:46Z","timestamp":1784523046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/509762-serum-orexin-a-levels-and-heart-rate-variability-parameters-in-newly-diagnosed-treatment-nave-type-2-diabetes-mellitus-a-case-control-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.112979","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}